期刊名称：PHARMACOGENOMICS
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Pharmacogenomics is a peer-reviewed journal presenting reviews and reports by the researchers and decision-makers closely involved in this rapidly developing area. Key objectives are to provide the community with an essential resource for keeping abreast of the latest developments in all areas of this exciting field. Pharmacogenomics focuses on those aspects that have the most direct relevance to the pharmaceutical industry and wider clinical community, including:
 |
|
The emergence of new pharmacogenomic initiatives and their impact on R&D and regulatory strategies
Emerging technologies for accessing and exploiting genomic information
Reviews of genotyping and clinical data in particular therapeutic areas
Development of novel diagnostic products and strategies
Pharmacogenomics is the leading source of commentary and analysis, bringing you the highest quality expert analyses from corporate and academic opinion leaders in the field. |
Instructions to Authors
Submission
Please submit manuscripts in Microsoft Word 2000 format via e-mail to the Commissioning Editor of the relevant journal. Figures should be submitted as Microsoft PowerPoint, Adobe Illustrator or Photoshop (*.eps). Graphs and charts can also be submitted as Microsoft Excel.
Copyright
As the author of your manuscript, you are responsible for obtaining permissions to use material owned by others. Since the permission-seeking process can be time-consuming, it is wise to request permission as soon as possible. A template permission letter is available upon request by contacting the Commissioning Editor of the relevant journal. Please send us photocopies of letters or forms granting you permission for the use of copyrighted material so that we can see that any special requirements with regard to wording and placement of credits are fulfilled. Please keep the originals for your files.
Instructions to Authors
1462-2416.pdf
Editorial Board
Editorial Advisory Board
Overseeing the editorial content and development of Pharmacogenomics is an Editorial Advisory Board, composed of many of the world's leading experts within the area of pharmacogenomics and pharmacogenetics.
Altshuler D: Whitehead Institute, USA
Bader JS: CuraGen, USA
Bailey D: Purely Proteins, UK
Bennett CF: Isis Pharmaceuticals, USA
Boehm B: University of Ulm, DE
Campbell DA: AstraZeneca, UK
Clayton CL: GlaxoSmithKline, UK
Cohen D: Novartis, USA
Dykes C: OpGen, USA
Freeman T: MRC Hinxton, UK
Gurwitz D: Tel-Aviv University, IL
Hakonarson H: deCODE Genetics, IS
Hardiman G: University of California, USA
Hein DW: University of Louisville, USA
Ishikawa T: Tokyo Institute of Technology, JP
Judson R: Genaissance, USA
Jung V: Biogen Idec, USA
Lennard MS: University of Sheffield, UK
Levenson V: Northwestern University, USA
Lindpaintner K: Hoffmann-La Roche, CH
Lipshutz RJ: Affymetrix, USA
Little S: DxS Ltd, UK
Liu L: Cambria Biosciences, USA
März W: University of Graz, DE
McLeod HL: University of Washington, USA
Murphy M: Gentris, USA
Osborne M: Millennium Pharmaceuticals, USA
Palfreyman M: NOVACE, USA
Plasterk R: Hubrecht Laboratories, NL
Poste G: Health Technology Networks, USA
Roberds SL: Pfizer, USA
Ruaño G: Genomas, USA
Salerno R: Wyeth, USA
Sim E: University of Oxford, UK
Warburg RJ: Foley & Lardner, USA
Winkelmann BR: Cardiology Group Frankfurt-Sachsenhausen, DE
Wolf CR: University of Dundee, UK
Xie H-G: University of Vanderbilt, USA
Zhao H: Yale University, USA
|
